Target intelligence / Profile preview

BK polyomavirus major capsid protein VP1 (VP1)

Target
VP1
Molecular classification
Structural protein, Viral capsid protein, Other
01

Overview

BK polyomavirus major capsid protein VP1 is the principal structural protein of the BK polyomavirus, self-assembling into pentamers that form the external shell of the icosahedral viral capsid with T=7 symmetry and a diameter of approximately 50 nm[2][4][7]. The capsid comprises 72 pentameric units of VP1 stabilized by intermolecular disulfide bonds, in association with minor structural proteins VP2 and VP3, and it encapsulates the viral DNA genome[2][7]. VP1 is responsible for virion attachment to host cells by binding specific sialic acid–containing ganglioside receptors (notably GT1b and GD1b) on the cell surface, facilitating viral entry predominantly via caveolin-mediated endocytosis[3][4]. In addition to its structural role, VP1 interacts with host cell factors and participates in the uncoating process inside the host cell, which is required for delivery of the viral genome to the nucleus for replication[4]. Due to its critical roles in the infectious process and immune recognition, VP1 is a key target for antiviral strategies, diagnostic assays, and vaccine development for BK polyomavirus–related diseases[5].

Other names
Major capsid protein VP1Major structural protein VP1BKPyV VP1Polyomavirus coat protein VP1
02

Mechanism of action

Experimental peptides inhibit viral infection by binding to the central pore of VP1 pentamers, blocking critical interactions required for viral infectivity[1].

03

Biological functions

Formation of the viral capsidVirion assemblyAttachment to host cell receptorsMediating virion internalization via ganglioside bindingInitiation of virion uncoating
04

Disease associations

Infection (BK polyomavirus-associated diseases including BK virus nephropathy, hemorrhagic cystitis, and related opportunistic infections in immunocompromised patients)
05

Safety considerations

Immune escape due to VP1 sequence variation[5]High immunogenicity may limit protein-based therapies or vaccines in certain hosts[5]
06

Interacting drugs

No approved drugs directly target VP1 in clinical practice as of July 2025, but research peptides (such as D1 min peptide derived from VP2/3) have been shown in vitro to inhibit VP1 function and viral infection[1].
07

Biomarkers

Detection of anti-VP1 antibodies (used for serological diagnosis of infection)[5]Presence of VP1 antigen in urine/blood (used in diagnostics of polyomavirus infection and disease monitoring)[5]

Beyond the preview

Go deeper on BK polyomavirus major capsid protein VP1 (VP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK polyomavirus major capsid protein VP1 (VP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call